STOCK TITAN
  1. Home
  2. News
  3. CLNN

Clene Inc - CLNN STOCK NEWS

Welcome to our dedicated news page for Clene (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clene's position in the market.

News
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Rhea-AI Summary
Clene Inc. presented significant evidence of repair and remyelination in multiple sclerosis patients treated with CNM-Au8 at the 2024 AAN Annual Meeting. The Phase 2 VISIONARY-MS LTE study showed improved clinical outcomes, cognitive function, vision, and structural evidence of repair and remyelination with long-term CNM-Au8 treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
Rhea-AI Summary
Clene Inc. and its subsidiary Clene Nanomedicine Inc. reported the publication of a study on the protein corona formed by CNM-Au8 gold nanocrystals. The corona aids in blood-brain barrier penetration, enhancing the drug's neuroprotective mechanism. The study revealed that the protein corona prevents aggregation, promotes colloidal stability, and prolongs circulation time in the blood. CNM-Au8's unique composition, enriched with apolipoproteins, facilitates brain delivery and has shown positive results in preclinical and clinical studies, with plans for a Phase 3 trial for ALS treatment in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
-
News
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Rhea-AI Summary
Clene Inc. (CLNN) announced discussions with FDA for accelerated approval of CNM-Au8® for ALS treatment. Long-term data showed significant reductions in plasma neurofilament levels and survival benefits. Financially, the company reported $35.0 million in cash as of Dec 31, 2023, with a grant of $45.1 million for an EAP in ALS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
earnings
News
Clene to Present at the 36th Annual ROTH Conference
Rhea-AI Summary
Clene Inc. and its subsidiary Clene Nanomedicine Inc. will participate in the 36th Annual ROTH Conference to discuss their focus on improving mitochondrial health and treating neurodegenerative diseases like ALS and MS. The presentation will be held on March 18, 2024, at The Ritz Carlton Laguna Niguel in California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
conferences
-
News
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
Rhea-AI Summary
Clene Inc. (CLNN) presents positive long-term clinical results for CNM-Au8 in treating multiple sclerosis at the ACTRIMS Forum. CNM-Au8 shows significant vision and cognition improvement over 35 months, well-tolerated with no serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
clinical trial
-
News
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Rhea-AI Summary
Clene Inc. reports significant survival benefits in ALS patients treated with CNM-Au8 in Expanded Access Programs. The treatment showed a 68% and 57% decreased risk of all-cause mortality compared to controls. The therapy was well-tolerated with no serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
News
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) reported positive long-term results for CNM-Au8® in the treatment of multiple sclerosis (MS) in the VISIONARY-MS trial. The treatment demonstrated significant improvement in vision and cognition through 35 months from randomization, with no significant safety concerns reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.69%
Tags
none
-
News
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) reported new data from the 12-month long-term open label extension (OLE) of the CNM-Au8® treatment arm in the HEALEY ALS Platform Trial, showing significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo, a 60% decreased risk of long-term all-cause mortality, and greater overall treatment effect in delaying the time to morbidity events in the highest risk participants based on baseline NfL levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.46%
Tags
none
-
News
Clene Provides Update on ALS Clinical Development Meeting With FDA
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) provided an ALS regulatory update from its recent meeting with the U.S. Food and Drug Administration (FDA) regarding CNM-Au8® for the treatment of ALS. The FDA determined that the initial findings on biomarker NfL reduction from the Phase 2 programs were insufficient to support accelerated approval at this time. Clene plans to provide supplemental data for further engagement with the FDA, including additional long-term clinical evidence and biomarker results in the first half of 2024. The company also supports ongoing CNM-Au8 compassionate use programs and plans to launch a Phase 3 ALS confirmatory study in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.46%
Tags
clinical trial
News
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) and its subsidiary Clene Nanomedicine Inc. announce the successful Phase 2 REPAIR clinical studies for CNM-Au8® in treating neurodegenerative diseases. The studies show significant increase in brain NAD+/NADH ratio, ATP levels, and phosphorylation potential, indicating favorable modulation of brain energy metabolites. The results are published in the Journal of Nanobiotechnology, signaling a significant advancement in the treatment of Parkinson’s disease and multiple sclerosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
Stock CLNN logo
Clene Inc

Nasdaq:CLNN

CLNN Rankings

#4802 Ranked by Market Cap
#4857 Ranked by Stock Gains
N/A Ranked by Dividends

CLNN Stock Data

46.20M
67.91M
40.13%
19.28%
0.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Salt Lake City

About CLNN

clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.